The results showed a significant cost reduction associated with natalizumab compared with ofatumumab and ocrelizumab and a positive trend in clinical improvements, including fewer relapses and less disability progression, alongside societal effects improvements such as increased patient productivity and reduced caregiver burden.
← all excerpts
Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis.
1
—
—